A Phase 1, Dose Escalation Study of Intravenous TK216 in Patients with Relapsed or Refractory Ewing Sarcoma

Clinical Trial Grant

Duke Scholars

Principal Investigator Richard Francis Riedel Medicine, Medical Oncology

Administered By

Duke Cancer Institute

Awarded By

Oncternal Therapeutics, Inc.

Start Date

March 7, 2018

End Date

September 16, 2022

Administered By

Duke Cancer Institute

Awarded By

Oncternal Therapeutics, Inc.

Start Date

March 7, 2018

End Date

September 16, 2022